Login / Signup

Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial.

Jiahui HuangYiwei TongJin HongOu HuangJiayi WuJianrong HeWeiguo ChenYafen LiXiaosong ChenKunwei Shen
Published in: Breast cancer research and treatment (2022)
Adding metformin to TEC didn't increase pCR rate and disease outcome in breast cancer patients with metabolic abnormality. However, additional metformin treatment with chemotherapy would prevent TC and LDL-C increase after NAT. Trial Registration ClinicalTrials.gov Identifier: NCT01929811.
Keyphrases
  • phase ii
  • open label
  • clinical trial
  • phase iii
  • locally advanced
  • placebo controlled
  • double blind
  • rectal cancer
  • study protocol
  • lymph node
  • low dose
  • squamous cell carcinoma
  • radiation therapy
  • high dose
  • young adults